Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312
Recruiting
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
07/28/2025
Locations: Arizona Arthritis and Rheumatology Associates PLLC, Avondale, Arizona +108 locations
Conditions: Polymyalgia Rheumatica
Register for Updates
EyeConic: Qualification for Cone-Optogenetics
NCT05294978
Recruiting
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Gender:
ALL
Ages:
All
Trial Updated:
07/28/2025
Locations: University of California San Francisco, Department of Ophthalmology, San Francisco, California +8 locations
Conditions: Retinal Dystrophies
Register for Updates
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948
Recruiting
This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer. The main purpose of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Medizinische Universität Innsbruck, Innsbruck, Not set +67 locations
Conditions: Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
Register for Updates
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217
Recruiting
This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day. All participants will receive 100 mg inhaled pirfenidone inhalation solution (AP01) taken twice daily using the eFlow Nebulizer System for until such a time that the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Westmead Hospital, Westmead, New South Wales +11 locations
Conditions: Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2025
Locations: RANGER & MATCH: Arizona Center for Hand Surgery, Phoenix, Arizona +48 locations
Conditions: Peripheral Nerve Injuries
Register for Updates
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
NCT06372821
Recruiting
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
07/25/2025
Locations: University College London Hospitals NHS Foundation Trust, London, Not set
Conditions: Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
Register for Updates
A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)
NCT06962852
Recruiting
This study is for people with cystic fibrosis who took part in a previous study with a medicine called BI 3720931. The main purpose of this study is to monitor the long-term health of participants who were treated with BI 3720931 in the previous study. Participants in this study do not receive additional treatment with BI 3720931. Participants who previously took BI 3720931 are in this study for 15 years. Participants who previously took placebo are in the study only until it is disclosed that... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: HOP Gui de Chauliac, Montpellier, Not set +9 locations
Conditions: Cystic Fibrosis
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Anchorage, Alaska +259 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
NCT06181240
Recruiting
The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Scripps Health, La Jolla, California +33 locations
Conditions: Coronary Artery Disease, Coronary Artery Calcification
Register for Updates
Rapid Examination of Acute CT
NCT06507124
Recruiting
CT scans are becoming increasingly prevalent in medicine. These are reviewed by radiologists and formal report provided. A recent survey suggests that non-radiologists are increasingly being expected to be able to interpret pathology on CT scans, however there is limited training provided in medical school and specialty training schemes. This study aims to qualitatively analyse how non-radiologists of different seniority and specialties approach CT body scan interpretation. This will be done by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: East Lancashire Hospitals NHS Trust, Blackburn, Not set
Conditions: Behavior
Register for Updates
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413
Recruiting
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Pinnacle Research Group, Anniston, Alabama +22 locations
Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Register for Updates
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277
Recruiting
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Patty & George Hoag Cancer Center, Newport Beach, California +278 locations
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Register for Updates